Lapto — Lapatinib 250 mg (150 Tablets) Heet Health Care

Lapto is prescribed for the treatment of HER2-overexpressing advanced or metastatic breast cancer:

• 🔹 In combination with capecitabine for patients who have received prior therapy including anthracyclines, taxanes, and trastuzumab.
• 🔹 In combination with aromatase inhibitors (e.g., letrozole) for postmenopausal women with hormone receptor-positive metastatic cancer.
• 🔹 In combination with trastuzumab for patients with disease progression on prior trastuzumab therapies.

Sales Unit: 1 pack containing 150 tablets, each with 250 mg of Lapatinib.

⚠️ APPLICATION INSTRUCTIONS:

• Dosage: The standard dose is typically 1250 mg (5 tablets) or 1500 mg (6 tablets) once daily, depending on the clinical protocol.
• Administration: Must be taken at least 1 hour before or 1 hour after a meal. Tablets should be swallowed whole.
• Dietary Restrictions: Avoid grapefruit and grapefruit juice, as they can significantly increase the concentration of the drug in the blood.
• Storage: Store in the original container below 30°C.

• ⛔ Cardiac Function: Pre-existing decrease in left ventricular ejection fraction (LVEF) requires careful monitoring.
• ⛔ Pregnancy: Highly hazardous to the fetus. Contraindicated during pregnancy and breastfeeding.
• ⛔ Hepatic Impairment: Severe liver dysfunction.
• Hypersensitivity to Lapatinib or any of its excipients.

Treatment requires professional medical supervision. Potential side effects include:

• 🤢 Gastrointestinal: Diarrhea (very common, requires monitoring for dehydration), nausea, and vomiting.
• 🧴 Dermatologic: Hand-foot syndrome, skin rash, and dry skin.
• 🟡 Hepatotoxicity: Elevated liver enzymes and bilirubin levels.
• 🫀 Cardiovascular: Risk of decreased left ventricular ejection fraction.